The European Medicines Agency today approved the first Omicron-adapted Covid-19 vaccines from drugmakers Pfizer/BioNTech and Moderna to start a booster dose campaign this winter to ward off a possible new wave. The vaccines “target Omicron’s BA.1 subvariant plus the original strain” of the coronavirus, which emerged in the Chinese city of Wuhan in 2019, the […]
Tag: Pfizer
Moderna v. Pfizer – BioNTech lawsuit over mRNA vaccine patent
The American Moderna is suing the also American Pfizer and the latter’s German partner, BioNTech, for violating technology patent laws regarding the mRNA platform, through which the two companies’ vaccine against Covid-19 was made. The suit is expected to be filed on Friday in a US court in Massachusetts and in a district court in […]
Pfizer: Acquires Global Blood Therapeutics for $5.4 billion
Pfizer announced Monday that it has reached an agreement to acquire blood disorder drugmaker Global Blood Therapeutics for $5.4 billion. Pfizer is looking to boost its production line to counter a potential slowdown in demand for its coronavirus products, as analysts expect due to a drop in cases. The company, which has cash on hand […]
Pfizer: Advanced negotiations to acquire Global Blood for $5 billion
Pfizer is in advanced talks to buy drugmaker Global Blood Therapeutics for about $5 billion, the Wall Street Journal reported Friday, citing sources with knowledge of the matter. Pfizer aims to seal the deal in the coming days, but there are other suitors for Global Blood, according to the report. Shares in Global Blood, which […]
Pfizer: Higher earnings and revenue in Q2 due to coronavirus drugs
Pfizer shares rose 0.3% in pre-conference trading as the drug giant reported higher second-quarter earnings and revenue, mainly due to its coronavirus drugs Comirnaty and Paxlovid. Net income rose to $9.91 billion, or $1.73 a share, from $5.56 billion, or 98 cents a share, a year ago. Stripping out one-time items, adjusted earnings per share […]
Pfizer/BioNTech: Trials of vaccine that treats up to the BA.2 Omicron subvariant
Pfizer Inc and BioNTech SE announced today that they have initiated mid-level trials of a modified Covid-19 vaccine that targets both the original variants and the BA.2 Omicron sub-variant. The vaccine is in an initial proof-of-concept study to gather more data (https://bit.ly/3veWPKn). The BA.4 and BA.5 subvariants combined are estimated to account for nearly 95% […]
The FDA has given full approval to Pfizer’s vaccine for children aged 12-15
The US Food and Drug Administration announced on Friday that it has granted full approval to Pfizer and BioNTech’s COVID-19 vaccine for adolescents aged 12 to 15, Reuters reports. The vaccine, sold under the brand name Comirnaty for adults, was available with an emergency license from May 2021 for the 12-15 age group. It will […]
Coronavirus: Pfizer and BioNTech sign agreement with US government to supply 105 million vaccine doses
Pfizer Inc. and BioNTech announced yesterday that they have signed a $ 3.2 billion (€ 3.6 billion) deal with the US government to supply 105 million doses of their COVID-19 vaccine. The installments are expected to be delivered by the end of the summer. The deal includes a vaccine adapted to the Omicron variant, and […]
BioNTech and Pfizer launch next-generation coronavirus vaccine test
Germany’s BioNTech, a Pfizer partner in Covid-19 vaccines, has announced that the two companies will begin testing next-generation vaccines in humans in the second half of the year that protect against a wide variety of coronaviruses. Their experimental work on vaccines that go beyond the current approach includes T-cell booster vaccines, designed primarily to protect […]
Pfizer: Acquires 8.1% of the French company Valneva
The American pharmaceutical group Pfizer has agreed to invest 90.5 million euros in the purchase of 8.1% of the French vaccine company Valneva, as the companies announced developments in their cooperation in the treatment of Lyme disease. Pfizer will acquire the stake in Valneva, which is also working on the coronavirus vaccine, at a price […]